Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Trotman

Showing results (11-20 of 148) with videos related to

Pageof 15
Sort By:
British Journal of Haematology|January 30, 2023
Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be moreIbrahim Tohidi-Esfahani, Judith Trotman
Seminars in Hematology|February 7, 2024
Integration of PET in DLBCLKatharine L Lewis, Judith Trotman
The Lancet. Haematology|December 28, 2020
The role of PET in first-line treatment of Hodgkin lymphomaJudith Trotman, Sally F Barrington
The Lancet. Haematology|March 26, 2021
2 + 2 in the long term: informing a new standard of care in 2021 for early stage, unfavourable Hodgkin lymphomaNicole Wong Doo, Judith Trotman
The New England Journal of Medicine|September 8, 2016
Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Judith Trotman, Massimo Federico
The Lancet. Haematology|December 6, 2016
Time to publish: challenging the performance of cooperative group lymphoma trialsMassimo Federico, Judith Trotman, Martin Dreyling
Eclinicalmedicine|November 10, 2020
Favourable outcomes for young lymphoma patients but age-old problems persistDr Praveen Gounder, Prof Judith Trotman
Cancer Journal (Sudbury, Mass.)|June 5, 2020
Advances in Treatment of Follicular LymphomaStefano Luminari, Judith Trotman, Massimo Federico
The Lancet. Oncology|January 8, 2019
Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' replyJudith Trotman, Sally F Barrington, Michel Meignan, et al.
Experimental Hematology & Oncology|August 22, 2024
Current and future therapies for follicular lymphomaPier Luigi Zinzani, Javier Muñoz, Judith Trotman
Pageof 15

Showing results (11-20 of 148) with videos related to

Sort By:
Pageof 15
British Journal of Haematology|January 30, 2023
Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be moreIbrahim Tohidi-Esfahani, Judith Trotman
Seminars in Hematology|February 7, 2024
Integration of PET in DLBCLKatharine L Lewis, Judith Trotman
The Lancet. Haematology|December 28, 2020
The role of PET in first-line treatment of Hodgkin lymphomaJudith Trotman, Sally F Barrington
The Lancet. Haematology|March 26, 2021
2 + 2 in the long term: informing a new standard of care in 2021 for early stage, unfavourable Hodgkin lymphomaNicole Wong Doo, Judith Trotman
The New England Journal of Medicine|September 8, 2016
Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Judith Trotman, Massimo Federico
The Lancet. Haematology|December 6, 2016
Time to publish: challenging the performance of cooperative group lymphoma trialsMassimo Federico, Judith Trotman, Martin Dreyling
Eclinicalmedicine|November 10, 2020
Favourable outcomes for young lymphoma patients but age-old problems persistDr Praveen Gounder, Prof Judith Trotman
Cancer Journal (Sudbury, Mass.)|June 5, 2020
Advances in Treatment of Follicular LymphomaStefano Luminari, Judith Trotman, Massimo Federico
The Lancet. Oncology|January 8, 2019
Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' replyJudith Trotman, Sally F Barrington, Michel Meignan, et al.
Experimental Hematology & Oncology|August 22, 2024
Current and future therapies for follicular lymphomaPier Luigi Zinzani, Javier Muñoz, Judith Trotman
Pageof 15